SALT LAKE CITY, Aug. 5, 2013 /PRNewswire/ -- Dynatronics Corporation (NASDAQ: DYNT) today announced the introduction of the new 25 Series electrotherapy/ultrasound therapy product line. This new line consists of four separate devices: the Dynatron 925, Dynatron 825, Dynatron 625 and Dynatron 525. These four units provide seven different types of electrotherapy treatments and three frequencies of ultrasound, including Dynatronics' proprietary three-frequency ultrasound transducers. They are capable of delivering between three and five separate treatments simultaneously, depending on the model. The ability to provide multiple treatments simultaneously is expected to be very helpful in busy clinics and training rooms, or for patients needing treatment of multiple areas of the body. "The introduction of the new 25 Series product line demonstrates Dynatronics' commitment to an aggressive R&D strategy and represents the company's first-ever complete line of modalities specifically targeting general-line dealers," stated Larry K. Beardall, executive vice president of sales and marketing. "This strategy will allow us to expand our distribution channel and open the door to more sales opportunities in our market space. As a result, we believe we will be successful in capturing greater market share in the physical medicine market." "Looking ahead, we plan to continue the release of additional capital products over the coming quarters," Beardall continued. "One of the most innovative products being developed has recently passed the 'proof of concept' stage of the R&D process and is being scheduled for introduction later this fall. Our decision to focus on our core strengths is designed to allow us to pursue a plan for expansion despite challenging market conditions." "Our commitment to introduce more new products in 2012 and 2013 than at any other time in our history is being realized," commented Kelvyn Cullimore Jr., Dynatronics' president and CEO. "The addition of the 25 Series products adds to the list of prior new product introductions, including the Solaris Plus family of therapy products, the Ultra Tables and the Quad 7 products. The introduction of these new products is a centerpiece of our strategic plan for increasing sales and profits." Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com. This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding expectations for future new product introductions and plans to expand distribution. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost-effective rates, and the risk factors listed from time to time in the company's SEC reports.